Autonomize AI Launches V3 Platform to Orchestrate Healthcare-Native AI at Scale

New updates have been reported about Autonomize AI.

Autonomize AI has released Version 3 of its Autonomize Intelligence Platform, positioning the company as a core infrastructure provider for healthcare-native AI agents across major U.S. health enterprises. The upgraded platform, already in production at three of the five largest U.S. health systems, adds deeper orchestration, more than 160 specialized healthcare AI agents, over 50 prebuilt connectors, and an embedded governance framework designed to activate AI-driven workflows within days.

At the center of Version 3 is a Knowledge Center that turns fragmented clinical, regulatory, and coverage data into a structured context graph of more than 10 million concepts, enabling agents to operate with longitudinal memory and real-time case awareness rather than handling tasks in isolation. Autonomize AI complements this with an AI Command Center for real-time KPI visibility and traceability, an AI Marketplace of versioned and governed agents for use cases such as utilization management and claims, and an AI Studio for low-code design and testing of workflows against real-world ground truth.

CEO Ganesh Padmanabhan frames the release as solving a key barrier to AI at scale in healthcare: organizations have historically had to manually stitch together models, workflows, and compliance, leading to stalled or siloed initiatives rather than enterprise-wide impact. By embedding compliance, auditability, and human oversight at every decision point, and by integrating into existing systems like EHRs and claims platforms via prebuilt connectors, Autonomize AI aims to reduce implementation risk and avoid disruption to core infrastructure while accelerating deployment.

Strategically, Version 3 reinforces Autonomize AI’s role as a continuously learning intelligence layer that spans clinical, operational, and business functions, addressing administrative bottlenecks in areas such as prior authorization, referral management, and payment integrity that have historically eroded clinician productivity and patient access. The company reports measurable outcomes at scale, including up to 55% faster clinical reviews, 60% faster decision turnaround, 30% fewer human errors, and 3–5x return on investment for customers within six to 12 months, which, combined with backing from healthcare-focused investors including Valtruis, Asset Management Ventures, Cigna Group Ventures, ATX Venture Partners, and TAU Ventures, suggests a strong growth trajectory as health systems seek enterprise-grade AI operations platforms.